Table 1.

Participant details.

	Age/sex	AME VA logMAR	FFE VA logMAR	Type	AME refraction	FFE refraction	Strab	Stereo (arc/sec)	Suppression	History	BDNF	First treatment
P1	43/F	1.00	0.00	Aniso	-0.25	+6.00/−2.25 × 180		Nil	Full	Patching age 7	Val66Met	Placebo
P2	32/M	1.20	-0.04	Mixed	+9.75	-0.25	Exo12Δ, hyper 11Δ	Nil	Full	Surgery 14 yrs, patching and spectacles 10-12 yrs	Val/val	Active
P3	47/M	0.64	-0.10	Mixed	Plano/−0.25 × 160	+1.75	Eso 10Δ	Nil	Full	Surgery 7 yrs	Val/val	Placebo
P4	19/F	0.34	-0.04	Aniso	+3.75/−1.75 × 180	+0.50/−0.25 × 180		60	Intermittent	Detected 11 yrs patching and VT	Val66Met	Active
P5	19/M	1.00	0.00	Strab	+4.50/−1.50 × 104	+3.50/−0.25 × 170	Eso 6Δ	Nil	Full	Spectacles and patching in childhood	Val/val	Active
P6	30/M	0.10	-0.08	Strab	Plano/−1.00 × 20	-2	Exo 20Δ	Nil	Full	Surgery 2 yrs, patching in childhood	Val/val	Active
P7	44/M	0.34	0.00	Mixed	+5.25/−1.25 × 90	+1.75/0.50 × 75	Exo 12Δ	Nil	Full	Surgery 2 and 10 yrs, spectacles until 15 yrs old	Val/val	Active

AME: amblyopic eye; FFE: fellow fixing eye; VA: visual acuity; exo: exotropia; eso: esotropia; hyper: hypertropia; aniso: anisometropic; strab: strabismic/strabismus; VT: vision training; BDNF: brain-derived neurotrophic factor.